文献速递泌尿系结石

PUrE随机对照试验1:输尿管软镜与体外冲击波碎石治疗≤10 mm肾下盏结石的临床与成本效果

The PUrE randomised controlled trial 1: Clinical and cost effectiveness of flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole stones of ≤10 mm.
PubMed 文献 · Eur Urol · 2025-04-22

这项多中心、开放标签、优效性随机对照试验比较了输尿管软镜(FURS)与体外冲击波碎石(ESWL)治疗≤10 mm肾下盏结石的效果。231例和230例患者分别随机接受FURS和ESWL。两组12周健康状态曲线下面积差异无统计学意义,FURS结石清除率更高(72% vs 36%),但ESWL更具成本效果。

要点

  • FURS组12周健康状态AUC为0.807,ESWL组为0.826,组间差异0.024(95%CI -0.004, 0.053),无统计学意义。
  • FURS完全结石清除率为72%,高于ESWL的36%。
  • FURS与ESWL的增量成本效果比为65 163英镑,在每QALY 20 000英镑阈值下ESWL有>99%概率具成本效果。

核心结论

  • PUrE RCT 1发现对于≤10 mm肾下盏结石,FURS与ESWL在健康状态方面无差异证据,FURS结石清除率更高,ESWL比FURS更具成本效果。

研究设计与样本

  • 务实性多中心、开放标签、优效性随机对照试验,比较FURS与ESWL治疗≤10 mm肾下盏结石的生活质量、临床和成本效果。
  • 共231例和230例患者分别随机分配至FURS组和ESWL组。

主要发现

  • 12周健康状态AUC均值:FURS组0.807(标准差0.205,n=164),ESWL组0.826(标准差0.207,n=188)。
  • 调整初始基线不平衡后,组间差异为0.024(95%CI -0.004, 0.053),为利于FURS的小幅无统计学意义差异。
  • 完全结石清除率FURS组为72%,ESWL组为36%。
  • FURS与ESWL的增量成本效果比为65 163英镑,在每QALY 20 000英镑阈值下ESWL有>99%概率具成本效果。

关键数值与推荐

  • 欧洲泌尿外科学会指南推荐ESWL和FURS作为肾下盏结石同等合适的一线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The European Association of Urology guidelines recommend that extracorporeal shockwave lithotripsy (ESWL) and flexible ureterorenoscopy (FURS) are equally appropriate first-line treatment options for lower pole renal stones (LPSs). We report a pragmatic multicentre, open-label, superiority randomised controlled trial (RCT) comparing FURS versus ESWL for quality of life, and clinical and cost effectiveness for LPSs of ≤10 mm-one of two RCTs that were part of the Percutaneous nephrolithotomy, flexible Ureteroscopy and Extracorporeal shockwave lithotripsy for lower pole kidney stone study (PUrE), with the other PUrE RCT 2 investigating larger stones. METHODS: In total, 231 and 230 patients were randomised to FURS and ESWL, respectively. The primary outcome was health status area under the curve (AUC) 12 wk after intervention using the EQ-5D-5L questionnaire. The primary economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained at 12 mo after randomisation. KEY FINDINGS AND LIMITATIONS: The mean health status AUCs over 12 wk were 0.807 (standard deviation [SD] 0.205) for FURS (n = 164) and 0.826 (SD 0.207) for ESWL (n = 188); the between-group difference was 0.024 (95% confidence interval -0.004, 0.053), a small nonsignificant difference in favour of FURS adjusted for an initial baseline imbalance. Complete stone clearance was higher with FURS (72%) than with ESWL (36%). The incremental cost-effectiveness ratio between FURS and ESWL was £65 163, meaning that at a threshold value of £20 000 per QALY, ESWL has a >99% chance of being cost effective. CONCLUSIONS AND CLINICAL IMPLICATIONS: PUrE RCT 1 found that there was no evidence of a difference in health status between FURS and ESWL for LPSs of ≤10 mm, with FURS leading to a higher stone-free rate. ESWL was more cost effective than FURS.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wiseman O, Smith D, Starr K, et al. The PUrE randomised controlled trial 1: Clinical and cost effectiveness of flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole stones of ≤10 mm. Eur Urol. 2025. PMID: 40268593. doi:10.1016/j.eururo.2025.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。